Sino Biopharmaceutical Limited (HKG: 1177)

Sino Biopharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	27,790	26,199	26,026	26,861	23,647	24,234
Revenue Growth (YoY)	8.68%	0.67%	-3.11%	13.59%	-2.42%	16.02%
Cost of Revenue	5,235	4,990	4,488	5,332	5,182	4,926
Gross Profit	22,555	21,210	21,539	21,529	18,465	19,308
Selling, General & Admin	11,689	11,067	11,709	12,704	11,629	11,797
Other Operating Expenses	4,996	4,704	4,444	4,193	2,738	2,558
Operating Expenses	16,685	15,770	16,153	16,896	14,366	14,355
Operating Income	5,870	5,439	5,386	4,633	4,098	4,953
Interest Expense	-355.55	-495.24	-429.49	-308.62	-323.37	-229.95
Interest & Investment Income	620.53	611.38	472.38	559.89	520.28	556.76
Earnings From Equity Investments	-399.33	-525.71	-152.98	13,631	-3.23	111.39
Currency Exchange Gain (Loss)	-33.43	-96.92	138.22	292.3	-	-
Other Non Operating Income (Expenses)	433.37	564.66	185.84	488.2	272.92	300.4
EBT Excluding Unusual Items	6,136	5,497	5,600	19,295	4,565	5,692
Gain (Loss) on Sale of Investments	-143.33	-12.81	-449.08	-265.38	443.44	-1.96
Gain (Loss) on Sale of Assets	56.77	62.55	3.47	-4.28	4.58	0.9
Asset Writedown	-	-	-19.4	-441.1	-	-
Other Unusual Items	-79.67	-137.25	80.08	-12.02	-	-
Pretax Income	5,970	5,410	5,215	18,573	5,013	5,691
Income Tax Expense	913.37	797.27	696.72	1,958	672.38	902.75
Earnings From Continuing Operations	5,056	4,613	4,518	16,615	4,341	4,788
Earnings From Discontinued Operations	1,948	484.76	484.47	-	-	-
Net Income to Company	7,005	5,097	5,003	16,615	4,341	4,788
Minority Interest in Earnings	-2,914	-2,765	-2,459	-2,006	-1,570	-2,026
Net Income	4,090	2,332	2,544	14,608	2,771	2,762
Net Income to Common	4,090	2,332	2,544	14,608	2,771	2,762
Net Income Growth	84.88%	-8.32%	-82.59%	427.17%	0.35%	-69.47%
Shares Outstanding (Basic)	18,451	18,529	18,622	18,769	18,800	18,811
Shares Outstanding (Diluted)	18,452	18,529	19,017	19,283	18,800	18,811
Shares Change (YoY)	-2.25%	-2.57%	-1.38%	2.57%	-0.06%	1.42%
EPS (Basic)	0.22	0.13	0.14	0.78	0.15	0.15
EPS (Diluted)	0.22	0.13	0.12	0.73	0.15	0.15
EPS Growth	103.10%	3.56%	-83.41%	397.00%	0.41%	-69.90%
Free Cash Flow	5,752	4,998	5,022	3,652	3,901	3,875
Free Cash Flow Per Share	0.31	0.27	0.26	0.19	0.21	0.21
Dividend Per Share	0.055	0.045	0.106	0.065	0.062	0.048
Dividend Growth	-38.97%	-57.24%	62.87%	5.59%	29.39%	1.92%
Gross Margin	81.16%	80.95%	82.76%	80.15%	78.08%	79.67%
Operating Margin	21.12%	20.76%	20.69%	17.25%	17.33%	20.44%
Profit Margin	14.72%	8.90%	9.77%	54.38%	11.72%	11.40%
Free Cash Flow Margin	20.70%	19.08%	19.30%	13.60%	16.50%	15.99%
EBITDA	6,701	6,379	6,254	5,453	5,661	6,275
EBITDA Margin	24.11%	24.35%	24.03%	20.30%	23.94%	25.89%
D&A For EBITDA	831.02	939.85	868.56	820.57	1,562	1,322
EBIT	5,870	5,439	5,386	4,633	4,098	4,953
EBIT Margin	21.12%	20.76%	20.69%	17.25%	17.33%	20.44%
Effective Tax Rate	15.30%	14.74%	13.36%	10.54%	13.41%	15.86%

Source: S&P Capital IQ. Standard template. Financial Sources.